Last reviewed · How we verify

Maintenance of Healing Erosive Esophagitis — Treatment Landscape & Competitive Intelligence

Maintenance of Healing Erosive Esophagitis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Maintenance of Healing Erosive Esophagitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Dexilant DEXLANSOPRAZOLE Takeda Proton Pump Inhibitor [EPC] (H+, K+)-ATPase 2009-01-01
Nexium esomeprazole AstraZeneca Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02
Pantoprazole Sodium Pantoprazole Sodium Pfizer Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme 2000-01-01
Prilosec omeprazole AstraZeneca (originally Astra AB) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14
Dexilant Dexilant Genuine Research Center, Egypt Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase
Omeprazol Omeprazol RenJi Hospital ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19
Pantoprazol Pantoprazol Northern Orthopaedic Division, Denmark ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1
Dexlan Dexlan Chang Gung Memorial Hospital Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Maintenance of Healing Erosive Esophagitis
  2. AstraZeneca · 1 drug in Maintenance of Healing Erosive Esophagitis
  3. AstraZeneca (originally Astra AB) · 1 drug in Maintenance of Healing Erosive Esophagitis
  4. Chang Gung Memorial Hospital · 1 drug in Maintenance of Healing Erosive Esophagitis
  5. Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Maintenance of Healing Erosive Esophagitis
  6. Genuine Research Center, Egypt · 1 drug in Maintenance of Healing Erosive Esophagitis
  7. Northern Orthopaedic Division, Denmark · 1 drug in Maintenance of Healing Erosive Esophagitis
  8. Pfizer · 1 drug in Maintenance of Healing Erosive Esophagitis
  9. RenJi Hospital · 1 drug in Maintenance of Healing Erosive Esophagitis
  10. Takeda · 1 drug in Maintenance of Healing Erosive Esophagitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Maintenance of Healing Erosive Esophagitis:

Cite this brief

Drug Landscape (2026). Maintenance of Healing Erosive Esophagitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/maintenance-of-healing-erosive-esophagitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing